Expertise in
16
conditions

Karel Pavelka

Prague, PR, CZ 
Expertise in
16
conditions
Prague, PR, CZ 

Overview

Karel Pavelka practices practicing medicine in Prague, Czech Republic.

Pavelka is highly rated in 16 conditions, according to our data. Their clinical expertise encompasses Arthritis, Rheumatoid Arthritis (RA), Axial Spondyloarthritis (AxSpA), Oophorectomy, and Hip Replacement.

They are actively involved in clinical research, co-authoring 258 peer reviewed articles and participating in 2 clinical trials.

Locations

Prague, PR, Czech Republic
Other Locations
Pilsen, PL, Czech Republic
Czech Republic

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

An International, Multicentre, Double-blind, Randomised Study of the Effect of Diacerein vs Celecoxib on Symptoms and Structural Changes in Symptomatic Knee Osteoarthritis Patients as Assessed by Magnetic Resonance Imaging
An International, Multicentre, Double-blind, Randomised Study of the Effect of Diacerein vs Celecoxib on Symptoms and Structural Changes in Symptomatic Knee Osteoarthritis Patients as Assessed by Magnetic Resonance Imaging
Enrollment Status: Completed
Publish Date: December 01, 2023
Intervention Type: Drug
Study Drugs: Diacerein, Celecoxib
Study Phase: Phase 3
A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance of Treatment Effect of Ixekizumab (LY2439821) in Patients With Axial Spondyloarthritis
A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance of Treatment Effect of Ixekizumab (LY2439821) in Patients With Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: June 13, 2022
Intervention Type: Drug
Study Phase: Phase 3
View 1 Less Clinical Trial

256 Total Publications

The impact of smoking and obesity on secukinumab effectiveness in psoriatic arthritis: real-world evidence from 1202 European patients.
The impact of smoking and obesity on secukinumab effectiveness in psoriatic arthritis: real-world evidence from 1202 European patients.
Journal: EULAR rheumatology open
Published: June 29, 2026

Frequently Asked Questions about Karel Pavelka

Is Karel Pavelka a top-rated expert for Arthritis?

MediFind is an objective health platform that identifies experts based on real-world data. Karel Pavelka is classified as an Elite expert for Arthritis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Karel Pavelka participate in research or clinical trials?

Yes. Karel Pavelka has published 256 articles and abstracts on conditions like Arthritis. You can view a list of Karel Pavelka's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Pavelka's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 15 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile